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Summary Preclinical studies have shown that the vitamin D analogue EB 1089 has significantly less calcaemic actvity than its parent
compound 1,25-dihydroxyvitamin D (1,25(OH)2D) and significant anti-tumouractivity. This phase I trial was designed to evaluate thecalcam ic
effect of the drug in patients with advanced cancer. EB 1089 was given to 36 patients with advanced breast and colorectal cancer in doses of
between 0.15 and 17.0jg i-2 day-'. Serial serum and urine calcium, unne creatinine and serum parathyroid hormone (PTH) were monitored.
Hypercalcaemia was seen in all patients receiving 17.0 9g m-n2 day-'. Hypercalcaemia attributable to EB 1089 was reversible by discontinuing
or reducing EB 1089 therapy. During the first 5 days of treatment, urine calcium (P= 0.0001) and serum-corrected calcium (P= 0.027) were
related to EB 1089 dose, whereas serum parathyroid hormone (P = 0.0001) showed an inverse relabonship. Twenty-one patients received
compassionate treatment for between 10 and 234 days. No complete or partal responses were seen. Six patients on treatmnent for more than
90 days showed stabilization of disease. EB 1089 was well tolerated and adverse events considered to be caused by EB 1089 were limited to
dose-dependent effects on calium metabolism. The dose estimated to be tolerable for most pabents from this study is around 7 igg m-2 day-'.
These data support previous work that has demonstrated EB 1089 to be significantty less calcaemic than 1,25-dihydroxyvtamin D3.
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The importance of 1,25-dihydroxyvitamin D, (l.25(OH,D,) in
calcium homeostasis has been known for many years, but recent
evidence has suggested an additional role in the control ofcellular
differentiation and proliferation (Bell, 1985: Reichel et al. 1989).
1,25(OH),D, has been shown to promote cellular differentiation
and inhibit proliferation. in vitro. of haematopoietic cells (Abe et
al. 1981: Bar et al. 1983: Rigby et al. 1984). cancer cells (Colston
et al. 1981: Frampton et al, 1983, Brehier et al. 1988) and the
epidermis (Hosomi et al. 1988). 1.25(OH),D, and its metabolites
have also been shown to inhibit cell proliferation in human rectal
mucosa (Thomas et al. 1992). In addition I,25(OH),D, has been
shown to inhibit tumour-induced angiogenesis (Majewski et al,
1993) and to inhibit the invasive potential of human breast cancer
cells in vitro (Hansen et al. 1994). Recently. 1,25(OH),D, was also
shown to induce apoptosis in human breast cancer and leukaemic
cell lines (Elstner et al. 1995: James et al. 1995). The hormone
mediates its action through the activation of the vitamin D
receptor. which is a member of the superfamily of nuclear recep-
tors (Mangelsdorf et al. 1995). The receptor-ligand complex
functions as a transcription factor and binds to DNA through inter-
action with vitamin D response elements. leading to either activa-
tion or suppression of target gene transcnption (Hanna and
Norman. 1994: Carlberg. 1995). Vitamin D receptor expression
has also been positively correlated with survival in breast cancer
(Berger et al. 1987).
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Laboratory studies have demonstrated that 1,25(OH),D, may be
of value in the treatment of hyperproliferative disorders such as
leukaemia. psoriasis. prostate cancer and breast cancer (Eisman et
al. 1987: Norman et al. 1990: Zhou et al. 1990: Kragballe. 1992;
SkoATonski et al, 1993). However, such treatment has frequently
resulted in the induction of hypercalcaemia at doses exceeding
more than a few micrograms per day.
In an attempt to circumvent this, a number of analogues have
been produced. mainly by minor structural modification ofthe side-
chain at the C-17 position. in order to depress calcaemic activity
while enhancing antiproliferative effects (Abe et al, 1987: Ostrem
et al. 1987: Binderup et al. 1988: Elstner et al. 1994). One such
compound. MC903. has been shown to be effective in the topical
treatment ofpsonrasis (Kragballe et al. 1991: Bagot et al. 1994) and
has also been beneficial in stabilizing locally advanced and cuta-
neous metastatic breast cancer (Bower et al. 1991). An analogue
with greater potential. EB 1089 (Figure 1). has been investigated
and has been found to inhibit the growth of breast cancer cells in
vitro and in vivo (Colston et al. 1992: James et al. 1994). These
studies showed that EB 1089 administration failed to cause signifi-
cant hypercalcaemia at doses that were capable ofcausing regres-
sion of mitrosomethylurea (NMU)-induced rat mammary tumours.
At a dose of 0.5 jg kg-' body weight the compound inhibited
tumour growth in the absence of hypercalcaemia. whereas the
equimolar dose of 1.25(OH),D, did not inhibit growth and
produced marked hypercalcaemia. Similarly. EB 1089 at a lower
dose of 0.1jIg kg-' demonstrated anti-tumour activity in a mouse
xenograph model ofcolon cancer (Akhter et al. 1997).
Toxicological evaluation of EB 1089 in mice. rats and minipigs
indicated no adverse effects apart from dose-related hyper-
calcaemia and its consequences. Genotoxicitv testing using the
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Figure 1 Strucures of 1,25-dihydroxyvtafin D3 and EB1089
reverse mutation assay, chromosome aberration test in cultured
human lymphocytes and the micronucleus test in mice were
negative.
PATIENTS AND MErHODS
The study was single-centre. open and non-controlled. with
sequential dose allocation.
Eligible patients were those with histologically proven
metastatic or locally advanced carcinoma of the breast or colon.
WHO performance level of 0-2, a life expectancy of at least 4
months, an albumin-corrected serum calcium < 2.65 in mm, and
adequate renal (urea < 15 mM), hepatic (bilirubin < 25 mM.
transaminases < 3 times upper limit of normal) and bone marrow
(Hb > 9.6g dl-. WBC > 3.0 x 109 1-1, platelets > 100 x 109 1-1)
function. Patients with a history of hypercalcaemia. disordered
calcium metabolism, diabetes mellitus and who had received any
anti-cancer therapy orcalcium-lowenrng therapy in the previous 3
weeks were excluded.
The study comprised two parts: (i) a per protocol treatment
phase and (ii) a compassionate treatment phase.
Table 1 Patent characteristcs
Number Per cent
Sex
Male 8 22.2
Female 28 97.8
Cancer type
Breast 25 69.4
Colon 11 30.6
Disease distibution
Locoregional 3 8.3
Bone metastases 15 41.7
Liver metastases 9 25.0
Other 9 25.0
Previous treatment
Chemotherapy 31 86.1
Hormone therapy 27 75.0
Radiotherapy 29 80.6
Surgery 34 94.4
WHO performance status
0 24 66.7
1 7 19.4
2 5 13.9
All 25 patents with breast cancer had received eiher one (three) two (ten) or
three or more (12) courses ofendocrine therapy foradvanced disea.
Fifteen of these patients had responded (eihercompletely or partially) in the
past at east once. Twenty of these pabents had also received conmbon
chedmo apy for advanced diseas (eight had received a single
combinati, six had received two dfferent cmrbatbons and six had
received from three to five different combiniabons). Ten of the patents with
coorectal carcinoma had received a singe course of chemothrapy: one
patient had received three separate courses. Two patents had responded.
Per protocol trement phase
All patients received EB 1089 solution containing either 2 jig or
5 gg ml-' for 5 days, given in two equal divided doses, in the
morning and evening, after fasting for 3 h. The first 11 patients
also received a single days' dosing, at the same dose level, 7 days
before commencing the 5-day dosing period. Patients were
followed up 21 days aftercompleting the 5-day dosing period.
Dosing started at a dose of0.15 jg m-2 day-'. This starting dose
was selected as it was comparable with therapeutic doses of
1,25(OH)2D3 and had been tolerated well by animals. Subsequent
dose levels increased by 30-50% each time for the following
patients and the maximum dose administered was 17 jg m-2 day-1.
Compassionate trebnent phase
Compassionate treatment for up to 1 year was allowed and
commenced at the end of the per protocol treatment. The same
dose level was to be given as that used in the per protocol phase.
but this could be reduced if hypercalcaemia had been recorded
during the per protocol phase or developed during compassionate
treatment. In patients who became hypercalcaemic. EB 1089 treat-
ment was stopped and the serum calcium allowed to return to
normal before treatment recommenced.
Calcium diet
All patients were seen by the hospital dietitian and commenced a
low-calcium diet (an estimated 500 mg day-') at the start of the
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Figre 2 Coelation of EB1089 dose in g rn- with (A) serum-coeced caium (n= 32), P= 0.0267; (B) urine calcium (n= 28), P= 0.0001;
(C) parathormne (n = 31), P = 0.0001; (D) serum creatinine (n = 34) P = 0.024 (slope 0.0015). P = values given are from linear regression on log ratio
(day 6/day 1) by dose lvel (ig m<-)
study. This was maintained during the per protocol and compas-
sionate treatment phases. Patients were given a diet sheet when
sent home and routinely questioned about compliance at follow-
up. All other calcium and vitamin D supplemnents were stopped
during the study.
Assessment of response, toxicity and monitoring
At the start of the trial, patients were staged by means of clinical
examination, chest radiograph, liver ultrasound and bone scan or
skeletal survey. Computerized tomography (C`T) scans were
obtained when relevant to assess disease. Assessment of response
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was carried out according to standard UICC criteria (Hayward et
al, 1987). Serum total calcium and blood pressure were monitored
closely on the first and last days of the repeated dosing period.
Blood was taken at 0, 1, 2, 3,4, 6, 8 and 12 h afterthe firstdose on
these days, as well as daily during the period of administration.
Clinical examination and electrocardiography were performed on
day 2, on the first and lastdays oftherepeateddosingperiod and 3
weeks later. Blood tests included routine haematology, biochem-
istry (including liver function tests) serum total calcium, albumin
and PTH (Incstar intact PH kit). Twenty-four-hour urine collec-
tions were made and calcium, phosphate, hydroxyproline
(Gordeladze et al, 1978) and creaiine excretion were measured
before receiving EB 1089 solution and were repeated on the day
after the repeated dosing period and 3 weeks later.
In the compassionate tatment phase, staging with relevant
scans was repeated every 8 weeks. During the compassionate
phase, clinical examination and routine blood chemistry were
performed either every 4 weeks or every 2 weeks if hypercal-
caemia developed.
Definition of hypercaklaemia and hypercalciuria
Corrected serum calcium was calculated using the formula [serum
total calcium + [(40 - serum albumin)] x0.02] mM ['. Hyper-
calcaemia was defined as a corected serum calcium > 2.65 mm
and severehypercalcaemia as acorrected serum calcium > 2.80 mml
(or two consecutive values of > 2.75 mm). Hypercalciuria was
defined as a 24 h urine calcium excretion > 75 inm).
During the per protocol phase, treatment with EB 1089 was
withdrawn ifatoxic event occurred. The parameters determining a
toxic event were either severe hypercalcaemia, hypercalciuria (for
the first 11 patients only) ora serious orunexpected adverse event
During compassionate treatment with EB 1089, dosage reduc-
tions (about 50%) were made ifsevere hypercalcaemia developed,
or clinical experience gained during the study suggested severe
hypercalcaemia could be expected at any dose level. Patients were
also to be withdrawn from teatment if they underwent disease
progression, defined as a greater than 25% increase in one dimen-
sion of measurable lesion, the appearance of new lesions or
significant clinical deterioration.
Detemination of maximum toleated dose (MD)
The MTD was determined by the continual reassessment method
(CRM).
Patients were entered sequentially and allocated to a dose level,
determined by the observed toxicity in the previously teated
patients, using an extension of the CRM (O'Quigley et al, 1990;
Moller, 1995). The method is based on a determination of an
acceptable level of toxic response (x = 40%) and the assumption
that the dose-response curve of the probability of experiencing a
severe toxicity could be described by a family ofmonotone func-
tions: f(x,a), depending on the dose,x, and a parameter, ca, monot-
onously in both x and a. For each new observation of toxicity or
no toxicity in a patient teated at dose x, the curve will be re-esti-
mated based on all the available observations by estimating the
parameter, a, andthe dosecorresonding tothe acceptable level of
toxic response (MTD) will be calculated by: p(MTD) =f(MTD, a)
= x, and given to the next patient
The family ofdose-onse curves for the dosedetermination is
f(z(x),a) =((tanhz(x))) + l)2)a, where z(x) is a linearfinction ofx,
nomalizing the interval so thatf(z,1) will take values in the interval
(0.05,0.70) forthe range ofdose levels considered. Thepriordistri-
bution of a before any patient entered is: g(a) = EXP (- a). The
distribution, g(a), will then beupdated foreach newobservation.
St_atcal methds
The mean relative change from the baseline to the end oftreatment
afterfive repeat doses was analysed forall laboratoryparameters
including the calcium profile (total seumm calcium, albumin-
corrected serumcalcium, urinecalcium, serumcreatnine andPITH)
by using a t-test on the log ratio (day 6/day 1). The relationship
between relative change and the dose was investigated using linear
regression. The distribution of the patients' disease status and the
rate of adverse events or hypercalcaemia at the end of treatment
was correlated with the diagnosis and site(s) of metastasis and
compared with dose levels using the x2 test orFisher's exact test.
The values at the end ofcompassionate treatment could not be
used to evaluate drug safety as most of the patients left the
compassionate treatment phase because ofhypercalcaemia and/or
medical deterioration. The analysis of dose dependency was
performed using linear regression analysis and using analysis of
variance on the time until leaving the study (after logarithmic
transformation) in order to obtain normal distributions.
Ethics
The study was conducted under clinical trials exemption and was
approved by the Riverside Research ethics committee.
RESULTS
Thirty-six patients all with progressive disease entered the study
between May 1993 and June 1995. Patient demographics are
shown in Table 1.
Per prontoco treatm
Elevenpatients received the single day's dosing followed by the 5-
day repeated dosing period at dose levels of 0.15-0.6 gg m-2.
Twenty-five patients received only the 5-day repeated dosing at
dose levels of0.9-17 ig in-2. The different positive disease sites,
as well as tumour sizes, were similarly distributed amongst the
dose steps.
Neither hypercalciuria nor hypercalcaemia was recorded with
one day's dosing. Eleven patients became hypercalcaemic during
the 5-dayrepeated dosing. Fourofthese patients had severe hyper-
calcaemia at doses of0.45, 12.5 and 17 (two) jg m-2. The patient
given 0.45 jg m-2 became severely hypercalcaemic after 3 days,
coincidental with a dramatic deterioration in her condition,
including a marked fall in serum albumin, leading to an increase in
corrected serum calcium, and died shortly after from the under-
lying disease.
Figure 2 shows the ratios of end of the 5-day repeated dosing
period (day 6) to baseline (day 1) for the following parameters:
corrected serum calcium, 24 h urine calcium, serum PTH, serum
creatinine against EB 1089 dose in jg m-2. P-values given are from
linear regression on log ratio (day 6/day 1) by dose level (.ug mr2).
There is a significant effect of EB 1089 on urinary calcium
(P = 0.0001), and on the cofrected serum calcium (P = 0.027), both
increasing with dose. Tlere is also a highly sigifint inverse
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Table 2 Patents in comfpassnte treatment phase
Sex Age Primary tumnour WHO Dose Days in compassonate Hypemcalcaemia Metastases Days in CT until
(years) performance 'gg mr- teatment (CT) p-
F
F
F
F
F
F
M
F
F
F
M
M
M
F
F
M
F
F
F
F
F
62
70
57
67
71
80
75
51
33
69
44
62
53
58
34
53
46
59
65
45
65
Breast
Breast
Breast
Breast
Breast
Breast
Colon
Breast
Breast
Breast
Appedxix
Colon
Colon
Colon
Breast
Colon
Breast
Colon
Breast
Breast
Breast
0
1
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0.15
0.15
0.3
0.45
0.6
0.6
1.2
1.2
1.5
1.5
2.1
2.1
4
4
5.5
7
7
12.5
17, 7b
17, 7, 4c
17, 7b
31
31
77
122
168
56
91
234
32
63
151
147
78
59
105
35
10
13
66
196
28
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
BO
BO
BBO
L B O
C
B
LO
LO
LO
L
L
L B
B
31
31
77
122
168
56
234
0
42
151
119
46
0
77
35
10
31
140
a
aPatient withdrew from study. bose redutons due to hypercalcaemia. cPatent withdrawn with risingcacium. bPatent withdrawn due to hypercalcaemia.
B, bone; L, liver, 0, other
Dose range (@g m-2)
0.6-3.0
4.0-12.5
-0- 17.0
Dose reductons (ig m-2)
17 to 7.0
7.0to4.0
1
:
_u8
-__;- -
---1
20 40 60 80 100
Days
120
Figure 3 Hypercalcaemic patients dunng the compassionate treatment phase. Values after the dotted lines indicate end-of-treatment measurements when
treatment continued bnger than the 120 days shown. 'Two patents with similar readings at these points
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relationship with serumparathyroid hormone level (P =0.0001) and
the relationship between EB 1089 and serum creainine also
achieved significance (P= 0.024).
Compasse _eament
Twenty-one patients received compassionate treatment for
between 10 and 234 days (mean 90± 62 days) (Table 2). Eleven
patients remained normocalcaemic throughout compassionate
treatment. Tenpatients became hypercalcaemic, which was severe
in six (Figure 3). It was transient in one case and resolved without
any dose changes. Of the remaining nine patients, four became
hypercalcaemic at doses they had tolerated during the 5-day
dosing period, and five patients had also developed hypercal-
caemia during the 5-day dosing period. In these nine patients,
hypercalcaemia was not significantly related to the diagnosis [six
(24%) breast cancer, three (27%) colorectal cancer] or the pres-
ence of bone metastasis [five (33%) with bone metastases, four
(19%) without]. Only one of these (receiving 12.5 ig m-2) was
symptomatic: she had bilateral hydronephroses with no known
cause, but had normal renal function. Hypercalcaemia usually
resolved within 7 days ofceasing treatment with EB 1089.
Estmate of MTD
The dose-response curve with respect to toxicity was estimated
after the study was completed, based on the last 11 patients who
received the 5-dayrepeateddosing atdose levels 7-17 jigmi-2. The
transformation of log dose was: Z(x) = (logl0(x) - 0.84) 1.89/
0.63 - 1.47 and the estinated MTD was 17.5 jig m- (Figure 4).
An additional dose-response curve was esfimated, based on all 25
patients treated at dose levels 2 0.9jig m-2 and for all treatment
periods, including compassionate teatment. Thetransformation of
log dose was changed to coverthe dose interval: [0.9-3.0jg m-2]:
Z (x) = (log10(x) - 0.05) 1.89/1.53 - 1.47. On this basis the esti-
mated MTD was 7 jg m-2 (Figure 4).
Anti-tumour effects
No clear-cut anti-tumour effects were seen in this study. Eighteen
patients received compassionate treatment forat least 30days: 12 at
the lowerdoses of0.15-3.0jig n-2 and six atdosesbetween4.0and
17 jg n-2. Sixpatients showed stabilization ofdisease inexcessof3
months. These patients received the following doses: 0.45, 0.6, 1.2,
2.1, 2.1 and 17 subsequently reduced to 7jg n-2 then 4jg r-2.
Fourhad breast cancer and two had colorectal cancer.
Safety monitoring
EB 1089 treatment had no effect on systolic or diastolic blood
pressure, heartrate orECG. Tlere was noeffect ofEB 1089 on the
indices of haematopoietic or hepatic function monitored. During
perprotocol tratment, EB 1089 did not affect urinary excretion of
creatinine, phosphate and hydroxyproline. During compassionate
treatment there was no effect on laboratory parameters, apart from
on serum calcium.
Adverse events
Tbree patients had noI-calcaemic adverse events during the 5-day
dosing and follow-up. These were pain andtiredness (one), dizziness
1.0
0.9
0.8
0.7
0.6-
x
_ 0.5
A
0.31
0.2
0.1 :
0.04 I
0 I
5 10 15
Dose (ig m-2)
20 25 30
Figure 4 Estiaed dose resporse curves forthe probabity of toxicity.
oEstite of MTD on 5-daydosing. *Esbirate of MTD based on all
teatment per
(one) and left-bundle branch block (one) in apatient who was found
subsequently tohave ischaemic heartdisease. Duringcompassionate
tratment, eight non-calcaemic adverse events were recorded in six
patients, two of whom had adverse events during the 5-day dosing
period and mprised nausea and vomiting (two), pain (two),
icreased pleural effusion (one), rsing alkali phos ase (one)
and raised gamma-glutamyltanspeptidase (one). None of these
events wasclearly related to EB 1089treatment
To ourknowledge, this is the first reported study ofa systemically
administerd synthetic analogue of vitamin D in the therapy of
human cancer. Administration ofEB 1089 solution was not associ-
ated with any toxicity clearly attributed to the drug other than
those abnormalities associated with calcium metabolism.
When EB 1089 solution was administerd foronly 5 days, treat-
ment-related hypercalcaemia developed in ten patients. Using the
data from the higher dose levels only, the MTD was detrmined as
17.5 jig m-2. However, prolonged treatment with EB 1089 solution
at such doses was invariably associated with hypercalcaemia. Of
the ten patients who became hypercalcaemic on compassionate
teatment, four did so at doses they had tolerated for 5 days.
Delayed hypercalcaemia was a feature of prolonged EB 1089
(longer than 5 days). Hypercalcaemia resolved, usually within 7
days, when treatment was withdrawn. The best estimate of the
MTD for prolonged tratment with EB 1089 solution from this
study is around 7 jig m-2. Preliminary data from phase II trials
currently underway confinn a dose range of 10-20jLg daily. This
dose is significantly higher than that recorded for 1,25(OH)2D3,
when hypercalcaemia is invariably observed at doses of 2 jig
(Vieth, 1990).
It is encouraging that the expected decrease in calcaemic
activity of EB 1089 relative to that of its parent compound,
(1,25(OH),D3), has translated into the clinical setting. Certainly
the dose esfimated to be tolerable to patients (7 jig m-2, corre-
sponding to around 0.2 jig kg-' in man) is similar to, or greater
than, those shown to have anti-tumour tumour effects in
animal models (Haq et al, 1993; Colston, 1994; DL Morris,
personal communication).
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Pharmacokinetic studies were not conducted in this study. No
suitable assay was available to measure EB 1089 in urine or
serum. However, the significant correlation ofEB 1089 dose with
serum calcium and inverse correlation with serum PTH indicates
adequate bioavailability ofthe drug.
The relationship between EB 1089 dose and serum creatnine
seen with acute (5 day) doses is not explained. However, this
funding is in accordance withodtertrials involving calcitriol, alpha-
calcidol and other analogues. These studies report reversible
increases m serum creatine, with other changes in measurements
of renal function, such as creatinine cleaance, not being demon-
strate (Tvedegaard et aL 1988; Bertoli et al, 1990). Creatinine
clearance was not detrmined in our study. However, it is reassuring
to note that when EB 1089 was given forprolonged periods during
compassionate treatment there was nochange in serum creanine.
We failed to observe any anti-tumour effects in our patients.
However, all patients had received anti-cancer therapy previously
and many of the breast cancer patients had been given more than
three different therapeutic regimens in the past. It is reasonable to
expect that the 'differentiation agents', such as EB 1089, are
unlikely to have a measurable effect in this setting. Responses to
these agents may be more likely in the earlier stages ofdisease or
in patients with minial disease.
Recent research on new synthetic vitamin D analogues clearly
shows the possibility of developing derivatives that separate
potent modulatory effects on cell growth and differentiation and
effects on calcium homeostasis, and has established an exciting
potential forthesecompounds astherapeutic agents in malignancy.
This study described the administration ofone ofthese agents, EB
1089, to cancer patients. Adverse events were limited to dose-
dependentpredictable effects oncalcium metabolism, andthedrug
can be given at doses similar to the doses that we judge, on the
basis ofanimal studies, are needed for anti-tumour activity.
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